Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study
Li X, Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo R, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho R, Kosten T, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study. BMC Medicine 2024, 22: 253. PMID: 38902735, PMCID: PMC11188255, DOI: 10.1186/s12916-024-03443-7.Peer-Reviewed Original ResearchConceptsRBANS total scoreRepetitive transcranial magnetic stimulationTranscranial direct current stimulationMDD patientsTotal scoreHDRS-24Transcranial direct current stimulation groupDepressive disorderImmediate memoryDepressive symptomsCognitive dysfunctionHamilton Depression Rating ScaleTreatment of cognitive dysfunctionDepressed response ratesDepression Rating ScaleCognitive enhancing effectsTreating cognitive dysfunctionImprove neurocognitive impairmentsActive rTMS groupDouble-blindSafety of repetitive transcranial magnetic stimulationTranscranial direct current stimulation treatmentMDD inpatientsRepeatable BatterySessions of treatmentEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38917366, DOI: 10.4088/jcp.24m15265.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleIntent-to-treatIntent-to-treat analysisStandard antidepressantsDepressive disorderPost hoc analysisBaseline Montgomery-Asberg Depression Rating ScaleInadequate response to standard antidepressantsSevere depressionPost hoc analysis of patientsDepression Rating ScaleMajor depressive disorderAnalysis of patientsAdverse eventsMontgomery-AsbergConsistent with prior studiesPlacebo-controlled trialRating ScaleEfficacy measuresPer-protocolIntent-to-treat populationTreatment adherencePhase 3 randomized controlled trialsAdjunctive treatmentMDDEnhancing post-traumatic stress disorder patient assessment: leveraging natural language processing for research of domain criteria identification using electronic medical records
Miranda O, Kiehl S, Qi X, Brannock M, Kosten T, Ryan N, Kirisci L, Wang Y, Wang L. Enhancing post-traumatic stress disorder patient assessment: leveraging natural language processing for research of domain criteria identification using electronic medical records. BMC Medical Informatics And Decision Making 2024, 24: 154. PMID: 38835009, PMCID: PMC11151516, DOI: 10.1186/s12911-024-02554-8.Peer-Reviewed Original ResearchConceptsNatural language processingPost-traumatic stress disorderPost-traumatic stress disorder patientsRDoC domainsLanguage processingAbnormal instancesLeverage natural language processingDiagnosis of post-traumatic stress disorderDomain criteriaSimilarity threshold valueF1-macro scorePositive valence systemsHeightened cue reactivityElectronic medical recordsClinical notesF1 scoreCue reactivityStress disorderRDoCValence systemsReal-timeMental health improvementDisease trajectoryExtraction researchSensorimotor disturbances